GenOway's preclinical models gain ground in the fight against obesity

Lyon-based genOway, listed on Euronext Growth, is experiencing significant growth thanks to its predictive preclinical models used in research against obesity and metabolic disorders. Faced with the increase in pharmaceutical investments in these areas, genOway is positioning itself as a key player with its humanized models. These models provide a better understanding of the effectiveness of drugs, such as those concerning the GLP-1R receptor, recently highlighted by a study published in Nature Medicine.

The growing interest in these pathologies has enabled genOway to triple its sales in 2024, demonstrating the relevance of its strategy and product range. This success is part of the ROUTE50+ plan, targeting organic growth of 20% per year. By focusing on the scientific quality of its models, genOway intends to maintain this momentum and achieve self-financed sales of at least €50 million by 2028.